Xcovery is presenting a poster entitled:

eXalt3: First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study

Yi-Long Wu, Tony S. Mok, Martin Reck, Heather A. Wakelee, Chris Liang, Fenlai Tan, Kimberly Harrow, Vance Oertel, Gary Dukart, Lieming Ding, Leora Horn

The overall study objective is to evaluate the efficacy and safety of ensartinib vs crizotinib in patients with ALK+ NCSLC that have received up to 1 prior chemotherapy regimen and no prior ALK TKI. Ensartinib exhibited favorable effectiveness in in vitro and in vivo studies, including mutations that are resistant or become resistant to crizotinib. The eXalt3 trial was initiated in June 2016 and over 42 sites have been activated. Xcovery is presenting updated preliminary data on the efficacy and safety of ensartinib.